Denmark's Novo Nordisk, the world's largest maker of diabetes drugs, on Thursday said it was suing Sanofi-Aventis for infringing patents related to the FlexPen insulin delivery device. Novo said it filed the lawsuit in a Delaware Federal court earlier this month. It seeks an injunction against Sanofi's OptiClik pen delivery system and accuses the French drug maker, the world's third-largest, and certain of its U.S., German and Swiss affiliates, of "willful and deliberate patent infringement." Novo's FlexPen is a widely used insulin delivery device in the United States and is used with several of the company's brands of injectable insulin. The OptiClik pen system is Sanofi's only insulin delivery device approved in the U.S. and is used with all of its U.S. insulin products. James Shehan, Novo's general counsel, said the case could go to trial in 2007.

Posted by GEN-ERIC at 12:07:01 am into the following categories: In The News

---

http://gen-eric.com/patents/htsrv/trackback.php/394

Name:

Email: (not displayed on this site)

Site/Url:

Comment text:

Allowed XHTML tags: <p, ul, ol, li, dl, dt, dd, address, blockquote, ins, del, a, span, bdo, br, em, strong, dfn, code, samp, kdb, var, cite, abbr, acronym, q, sub, sup, tt, i, b, big, small>

URLs, email, AIM and ICQs will be converted automatically.

Options:
Auto-BR (Line breaks become <br />)
Remember me (Set cookies for name, email & url)